Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
Expert Rev Pharmacoecon Outcomes Res
; 16(2): 153-66, 2016.
Article
en En
| MEDLINE
| ID: mdl-26681527
ABSTRACT
Secukinumab represents the first IL-17A antagonist among the available biologic therapies approved for moderate-to-severe plaque psoriasis management. Secukinumab demonstrated greater efficacy over placebo, etanercept and ustekinumab in patients that had limited benefit from non-biologic systemic therapies and phototherapy. Despite standard-of-care systemic therapies being more likely to be cost-effective at this time, a Canadian cost-utility analysis found secukinumab to display benefit in quality-of-life gains in moderate-to-severe plaque psoriasis patients, and greater cost-effectiveness when compared to other biologic systemic therapies. Determination of the true economic value of secukinumab amongst the available therapies for moderate-to-severe plaque psoriasis will require continued economic evaluation.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Fármacos Dermatológicos
/
Anticuerpos Monoclonales
Tipo de estudio:
Clinical_trials
/
Health_economic_evaluation
Límite:
Humans
Idioma:
En
Revista:
Expert Rev Pharmacoecon Outcomes Res
Asunto de la revista:
FARMACOLOGIA
Año:
2016
Tipo del documento:
Article
País de afiliación:
Canadá